Adezmapimod

(Synonyms: SB 203580; RWJ 64809)
607 Cited Publications
Customer Review

Based on 607 publication(s) in Google Scholar

Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator.

For research use only. We do not sell to patients.

  • Purity: 99.93%
  • CAS No.: 152121-47-6
  • Formula: C21H16FN3OS
  • Molecular Weight:377.43
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need

Publications Citing Use of MedChemExpress (MCE) Adezmapimod

More
Customer Validation & Images
IFWBIHCRT-PCR
  • RT-PCR
  • WB
  • RT-PCR
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • IF
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • IHC
  • WB
  • WB
  • WB
  • WB
  • WB
  • IF
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00